<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096369</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000393444; V-10604</org_study_id>
    <nct_id>NCT00096369</nct_id>
  </id_info>
  <brief_title>Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer</brief_title>
  <official_title>An Exploratory Study to Identify Potential Surrogate Endpoint Biomarkers That Are Modulated by Tamoxifen vs. Placebo in Women With an Increased Risk for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development or recurrence of cancer. The use of tamoxifen may be effective in preventing&#xD;
      breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying tamoxifen to see how well it works&#xD;
      compared to placebo in preventing breast cancer in women who are at increased risk for the&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare molecular markers of proliferation and apoptosis in breast epithelial tissue of&#xD;
           women at increased risk for breast cancer treated with tamoxifen vs placebo.&#xD;
&#xD;
        -  Compare the modulation of markers of genomic instability in breast epithelial tissue of&#xD;
           patients treated with these drugs.&#xD;
&#xD;
        -  Compare serum levels of IGF-1, IGF-2, and IGFBP-3 of these patients at baseline and&#xD;
           after treatment with these drugs.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are stratified according to estimated 5-year breast cancer risk (1.67-5% vs ≥ 5%), presence&#xD;
      of atypical ductal hyperplasia (yes vs no), and menopausal status (premenopausal vs&#xD;
      postmenopausal). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral tamoxifen once daily.&#xD;
&#xD;
        -  Arm I: Patients receive oral placebo once daily. Treatment in both arms continues for 3&#xD;
           months in the absence of invasive breast cancer or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo core needle biopsy and fine needle aspiration biopsy at baseline and then at&#xD;
      the completion of study treatment (for premenopausal patients); exactly 84 days after the&#xD;
      first biopsy (for postmenopausal patients); or on the first or second day of the menstrual&#xD;
      cycle on or after 84 days (during the third menstrual cycle) after the first dose of study&#xD;
      medication (for patients with irregular menses).&#xD;
&#xD;
      Patients are followed at 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 130 patients (65 per arm) will be accrued for this study within&#xD;
      30 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    accrual goal not met&#xD;
  </why_stopped>
  <start_date type="Actual">February 2000</start_date>
  <completion_date type="Actual">March 15, 2007</completion_date>
  <primary_completion_date type="Actual">March 15, 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of hormones and binding proteins as measured by ELISA, IHC, and TUNEL at baseline and 3 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of proliferation and apoptosis in breast cells as measured by quantitative MSP at baseline and 3 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Promoter-region methylation as assessed by microarrays at baseline and 3 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression</measure>
  </primary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  At increased risk for breast cancer, as defined by 1 of the following criteria:&#xD;
&#xD;
               -  Histologically confirmed lobular carcinoma in situ (LCIS) treated by local&#xD;
                  excision only&#xD;
&#xD;
               -  Composite increased breast cancer risk of ≥ 1.67% over 5 years, based on the&#xD;
                  following criteria:&#xD;
&#xD;
                    -  Age&#xD;
&#xD;
                    -  Number of first-degree female relatives with breast cancer&#xD;
&#xD;
                    -  One or more prior breast biopsies&#xD;
&#xD;
                         -  Fine-needle aspiration cytology of a non-cystic lesion in lieu of an&#xD;
                            open biopsy is considered a biopsy&#xD;
&#xD;
                    -  Prior diagnosis of atypical hyperplasia of the breast&#xD;
&#xD;
                    -  Age at first live birth&#xD;
&#xD;
                    -  Nulliparity&#xD;
&#xD;
                    -  Race&#xD;
&#xD;
                    -  Age at onset of menarche&#xD;
&#xD;
          -  No prior or suspected invasive breast cancer or ductal carcinoma in situ&#xD;
&#xD;
          -  No clinical evidence of malignancy by physical examination, including a breast&#xD;
             examination within the past 3 months&#xD;
&#xD;
          -  No evidence of suspicious or malignant disease or uncharacterized lesions on bilateral&#xD;
             mammogram within the past 6 months&#xD;
&#xD;
          -  Normal gynecologic examination, including a bimanual pelvic examination and, if&#xD;
             indicated, pap smear within the past 12 months&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  35 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Premenopausal and ovulating*, defined as having regular menses for the past 6 months&#xD;
             OR irregular menses with follicular phase (i.e., day 3) follicle-stimulating hormone&#xD;
             level &lt; 20 mIU/mL OR&#xD;
&#xD;
          -  Postmenopausal NOTE: * Ovulation is determined by day 21 progesterone level &gt; 3 ng/mL&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Complete blood count normal&#xD;
&#xD;
          -  No active bleeding disorder (e.g., qualitative or quantitative platelet abnormality,&#xD;
             hemophilia, or von Willebrand's disease)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Liver function tests normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No prior deep-vein thrombosis except a single occurrence related to lower extremity&#xD;
             trauma&#xD;
&#xD;
          -  No prior cerebral vascular accident&#xD;
&#xD;
          -  No prior transient ischemic attack&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No prior pulmonary embolus except a single occurrence related to lower extremity&#xD;
             trauma&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No saline or silicone breast implants&#xD;
&#xD;
          -  No known allergy to tamoxifen&#xD;
&#xD;
          -  No macular degeneration&#xD;
&#xD;
          -  No malignancy within the past 5 years except basal cell or squamous cell skin cancer&#xD;
             or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No nonmalignant disease that would preclude administration of tamoxifen&#xD;
&#xD;
          -  No psychiatric condition, including a history of clinical depression or addictive&#xD;
             disorder, that would preclude giving informed consent or study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective nonhormonal contraception during and for 3 months&#xD;
             after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior systemic adjuvant chemotherapy for LCIS&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior tamoxifen, raloxifene, or other selective estrogen-receptor modulators&#xD;
&#xD;
          -  At least 3 months since prior and no concurrent use of any of the following drugs:&#xD;
&#xD;
               -  Estrogen or progesterone replacement therapy&#xD;
&#xD;
               -  Oral contraceptives&#xD;
&#xD;
               -  Androgens&#xD;
&#xD;
               -  Luteinizing hormone-releasing hormone analogs&#xD;
&#xD;
               -  Prolactin inhibitors&#xD;
&#xD;
               -  Antiandrogens&#xD;
&#xD;
               -  Steroids&#xD;
&#xD;
          -  No concurrent steroids for asthma&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for LCIS&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior bilateral prophylactic mastectomy&#xD;
&#xD;
          -  No prior mastectomy for LCIS&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent nonhormonal medications allowed&#xD;
&#xD;
          -  No concurrent warfarin or cholestyramine&#xD;
&#xD;
          -  No prior or concurrent participation in any other cancer prevention study&#xD;
&#xD;
               -  Patients treated with placebo on protocol NSABP-P-1 are eligible&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Euhus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oklahoma University Cancer Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <last_update_submitted>January 22, 2019</last_update_submitted>
  <last_update_submitted_qc>January 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>lobular breast carcinoma in situ</keyword>
  <keyword>breast cancer in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

